TrialKidney international2015

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.

Christoph Licht et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.